Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

Exclusion Criteria

• •Hypersensitivity to test product (RPH-104) and/or its ingredients/excipients.
• •Pregnancy and breastfeeding.
• •Verified chronic heart failure (The American Heart Association / The American College of Cardiology (AHA/ACC) C-D class, New York Heart Association (NYHA) Functional class (FC) III-IV)
• •Pre-existing severe valvular heart disease according to the investigator's assessment.
• •Pre-existing left ventricular (LV) dysfunction (ejection fraction (EF)\<40%)
• •History of STEMI
• •Complications of acute myocardial infarction (MI) in the form of acute left ventricular failure and cardiogenic shock defined as stable blood pressure decrease (SBP\<90 mm Hg) associated with signs of hypoperfusion as well as cases when inotropic and/or mechanical support is required to maintain SBP; and / or unstable hemodynamics.
• •Active infections (acute or chronic); active tuberculosis.
• •Recent (less than 5 half-life periods) or current administration of colchicine, as well as agents with an immunosuppressant mechanism of action, including, but not limited to:
• •glucocorticoids at doses of \> 1 mg/kg of methylprednisolone equivalent, tumor necrosis factor-alfa (TNFα) blockers, Interleukin-1 (IL-1) and other biological drugs, cyclosporine and other immunosuppressants. Non-steroidal anti-inflammatory drugs (NSAIDs) are allowed.
• •Immunization with live vaccines within 90 days prior to the study product administration.
• •Chronic systemic autoimmune or autoinflammatory diseases
• •Suspected necessity in cardiosurgery.
• •Oncology (or diagnosis of oncology within the last 5 years).
• •History of organ transplantation or necessity in transplantation at the screening initiation or scheduled transplantation during the study.
• •Neutropenia (absolute neutrophil count \<1800/mm\^3).
• •Participation in another clinical study within the previous 3 months prior to Screening visit.
• •Other medical (including mental) conditions or abnormal laboratory findings which may increase the risk for the subject associated with the study participation or administration of the study products or which may affect interpretation of the study results and, according to the investigator, render the subject ineligible for the study.\*
• •\*If, in the Investigator's opinion, administration of a non-live COVID-19 (SARS-CoV-2) vaccine increases the risk for the patient related to his/her participation in the study, the Investigator can make a decision not to include this patient into the study.
• •The subjects working at the study site or subjects working for Sponsor directly involved in this clinical study.